Advertisement

Picture [iito] Männer Ballett 650x80px
Document › Details

BioGeneration Ventures B.V.. (6/24/20). "Press Release: BioGeneration Ventures Closes BGV IV Fund at €105 Million". Naarden.

Organisations Organisation BioGeneration Ventures B.V. (BGV)
  Organisation 2 Bristol-Myers Squibb Co. (BMS) (NYSE: BMY)
  Group Bristol-Myers Squibb (BMS) (Group)
Products Product venture capital
  Product 2 LIFE SCIENCES
Persons Person van Wezel, Edward (BioGeneration Ventures 201710 Managing Partner before Macrozyme 200511 CEO)
  Person 2 Toyne-Sewell, Melanie (Instinctif Partners 201509)
     


> Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq

> Investment focus on entrepreneurial innovation in therapeutics in Europe

> Total assets under management >€220 million ($250m)


BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at €105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund’s original target.

The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, Schroder Adveq and the European Investment Fund. New investors to BGV IV include Industriens Pension and KfW Capital.

BGV is one of the largest VC funds in Europe focused on early investments in new bio-technology companies, with over € 220 million assets under management. Its team has broad experience in investment, life sciences, business development, and commercial operations. It also draws on experienced biotech entrepreneurs as venture partners and advisors, to the benefit of its portfolio companies.

The Company’s approach is to partner with scientists from major European institutions and entrepreneurs. The aim is to build new companies, around either single assets or technology platforms with the goal of creating transformational new medicines. This strategy is supported by the strong collaboration between BGV and Forbion, providing a platform across early- to late-stage companies.

The investment strategy for the BGV IV fund will follow the same successful path as BGV’s other funds, which have resulted in innovative new medicines reaching patients and yielded significant returns for investors.

Portfolio successes of earlier BGV funds include Acerta Pharma, which was acquired by AstraZeneca for up to $7bn and whose lead product Calquence® is now approved and marketed in the US, and Staten Biotechnology, which signed a €430 million exclusive option deal with Novo Nordisk. Other companies in the current BGV portfolio include NorthSea Therapeutics, Azafaros, Varmx, and Confo Therapeutics.

Edward van Wezel, BGV’s Managing Partner said:

“Over the last few years, BGV has demonstrated that investing in early-stage companies in Europe can bring innovative science to meet patients’ needs worldwide as well as financial value to investors. With this new fund, we are pleased to have the backing of some of our long-standing investors; we also welcome our new investors, Industriens Pension and KfW Capital. The early-stage science coming out of European Institutions is second to none and we are working with those at the forefront of their fields. We believe we can make a significant difference to companies in helping them translate promising science into transformational new medicines.”

Frederik Fischer Hjerl, Investment Manager at Industriens Pension, added:

“As a new investor to the BGV fund, we have had a lot of focus at the BGV team’s strong track record and their approach towards early innovation. There is an urgent demand for new medicines which might accelerate the level of innovation coming out of research institutions across Europe. Having an experienced team like BGV, which in multiple occasions has proven capable of identifying and nurturing the potential future stars, is crucial to bringing new ideas forward. We look forward to working with BGV to help bring new medicines through.“


For further information:

BioGeneration Ventures
Edward van Wezel
E-mail: info@biogeneration.vc
Tel: +31 35 69 930 00

Instinctif Partners (For other European media)
Melanie Toyne-Sewell / Phil Marriage / Kiki Zaccagnini
E-mail: BGV@instinctif.com
Tel: +44 20 7457 2020


About BioGeneration Ventures (BGV)

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €220 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.

BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.

BGV is based in Naarden, The Netherlands. For more information, please see the website: www.biogenerationventures.com


BGV

Gooimeer 2-35
1411 DC Naarden
The Netherlands

Contact

E: info@biogeneration.vc
T: +31 (0) 35 699 30 00
Follow us
https://nl.linkedin.com/company/biogeneration-ventures

   
Record changed: 2020-07-27

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for BioGeneration Ventures B.V. (BGV)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top